Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects With Relapsed or Refractory Aggressive B-Cell Malignancies

Next Previous
Search
Trial Profile

Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects With Relapsed or Refractory Aggressive B-Cell Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ONCT-808 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
  • Focus Adverse reactions
  • Sponsors Oncternal Therapeutics, Inc.

    • Most Recent Events

    • 12 Sep 2024 According to an Oncternal Therapeutics media release, based on the available clinical data and capital requirements for continued development, the Company has decided to terminate ONCT-808 for the treatment of patients with aggressive B-cell lymphoma study.
    • 12 Sep 2024 Status changed from recruiting to discontinued, according to an Oncternal Therapeutics media release.
    • 12 Sep 2024 Results of interim analysis published in an Oncternal Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top